{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:56:48Z","timestamp":1792065408060,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.nrleng.2026.502083","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:12:19Z","timestamp":1777993939000},"page":"502083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["ADAM10 and its role in Alzheimer disease"],"prefix":"10.1016","volume":"41","author":[{"given":"P.","family":"Ag\u00fcero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"G\u00f3mez Tortosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2026.502083_bib0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.nrleng.2026.502083_bib0010","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","article-title":"Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease","volume":"85","author":"Palmqvist","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2026.502083_bib0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/15622975.2017.1375556","article-title":"Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the consensus of the task force on biological markers in psychiatry of the World Federation of Societies of Biological Psychiatry","volume":"19","author":"Lewczuk","year":"2018","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.nrleng.2026.502083_bib0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.nrleng.2026.502083_bib0025","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.nrleng.2026.502083_bib0030","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/349704a0","article-title":"Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease","volume":"349","author":"Goate","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.nrleng.2026.502083_bib0035","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/375754a0","article-title":"Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease","volume":"375","author":"Sherrington","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.nrleng.2026.502083_bib0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s Disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.nrleng.2026.502083_bib0045","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/biomedicines12051096","article-title":"Passive anti-amyloid beta immunotherapies in Alzheimer\u2019s disease: from mechanisms to therapeutic impact","volume":"12","author":"Schreiner","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.nrleng.2026.502083_bib0050","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease","volume":"378","author":"Egan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2026.502083_bib0055","unstructured":"UniProt [Internet]. UniProtKB entry: O14672 - ADA10 HUMAN [Accessed 8 April 2023]. Available from: https:\/\/www.uniprot.org\/uniprot\/O14672."},{"key":"10.1016\/j.nrleng.2026.502083_bib0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12974-018-1255-9","article-title":"Levels of ADAM10 are reducedin Alzheimer\u2019s disease CSF","volume":"15","author":"Sogorb-Esteve","year":"2018","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.nrleng.2026.502083_bib0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrn.2016.7","article-title":"TREM2 variants: new keys to decipher Alzheimer disease pathogenesis","volume":"17","author":"Colonna","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.nrleng.2026.502083_bib0070","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3233\/JAD-170061","article-title":"The role of ADAM10 in Alzheimer\u2019s disease","volume":"58","author":"Yuan","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.nrleng.2026.502083_bib0075","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.mam.2008.08.001","article-title":"The ADAM metalloproteinases","volume":"29","author":"Edwards","year":"2008","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.nrleng.2026.502083_bib0080","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/hmg\/11.21.2615","article-title":"The disintegrin\/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts","volume":"11","author":"Hartmann","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nrleng.2026.502083_bib0085","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing","volume":"51","author":"Kunkle","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.nrleng.2026.502083_bib0090","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41588-022-01208-7","article-title":"Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer\u2019s disease","volume":"54","author":"Holstege","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.nrleng.2026.502083_bib0095","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1093\/hmg\/ddp323","article-title":"Potential late-onset Alzheimer\u2019s disease-associatedmutations in the ADAM10 gene atenuate {alpha}-secretase activity","volume":"18","author":"Kim","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nrleng.2026.502083_bib0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuron.2013.08.035","article-title":"ADAM10 missense mutations potentiate \u03b2-amyloid accumulation by impairing prodomain chaperone function","volume":"80","author":"Suh","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.nrleng.2026.502083_bib0105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.brainres.2011.09.008","article-title":"Genetic association between ADAM10 genepolymorphism and Alzheimer\u2019s disease in a Northern Han Chinese population","volume":"1421","author":"Song","year":"2011","journal-title":"Brain Res"},{"key":"10.1016\/j.nrleng.2026.502083_bib0110","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3389\/fgene.2018.00540","article-title":"Influence of ADAM10 polymorphisms on plasma level of soluble receptor for advanced glycation end products and the association with Alzheimer\u2019s disease risk","volume":"9","author":"Huang","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.nrleng.2026.502083_bib0115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ajhg.2008.10.008","article-title":"Genome-wide association analysis reveals putative Alzheimer\u2019s disease susceptibility loci in addition to APOE","volume":"83","author":"Bertram","year":"2008","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nrleng.2026.502083_bib0120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13195-020-00708-0","article-title":"\u03b1-Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer\u2019s disease","volume":"12","author":"Ag\u00fcero","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.nrleng.2026.502083_bib0125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.neurobiolaging.2010.03.003","article-title":"Evidence against a role for rare ADAM10 mutations in sporadic Alzheimer disease","volume":"33","author":"Cai","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.nrleng.2026.502083_bib0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076113","article-title":"ADAM10 Gene Variants in AD Patients and Their Relationship to CSF Protein Levels","volume":"24","author":"Ag\u00fcero-Rabes","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nrleng.2026.502083_bib0135","doi-asserted-by":"crossref","first-page":"2229.e1","DOI":"10.1016\/j.neurobiolaging.2012.03.013","article-title":"ADAM10 expression and promoter haplotype in Alzheimer\u2019s disease","volume":"33","author":"Bekris","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.nrleng.2026.502083_bib0140","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1097\/00001756-200211150-00008","article-title":"Levels of beta-secretase BACE and alpha-secretase ADAM10 mRNAs in Alzheimer hippocampus","volume":"13","author":"Gatta","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.nrleng.2026.502083_bib0145","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2174\/1567205014666170203093219","article-title":"Apolipoprotein E-mediated modulation of ADAM10 in Alzheimer\u2019s disease","volume":"14","author":"Shackleton","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.nrleng.2026.502083_bib0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052416","article-title":"ADAM10 plasma and CSF levels are increased in mild Alzheimer\u2019s disease","volume":"22","author":"Pereira Vatanabe","year":"2021","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.nrleng.2026.502083_bib0155","article-title":"ADAM10: biomarker of mild cognitive impairment but not of cognitive frailty","volume":"149","author":"Vatanabe","year":"2021","journal-title":"ExpGerontol"},{"key":"10.1016\/j.nrleng.2026.502083_bib0160","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-020-00750-y","article-title":"ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study","volume":"13","author":"Oliveira Monteiro","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.nrleng.2026.502083_bib0165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF03402076","article-title":"[alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients","volume":"8","author":"Colciaghi","year":"2002","journal-title":"Mol Med"},{"key":"10.1016\/j.nrleng.2026.502083_bib0170","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000345983","article-title":"ADAM10 as a biomarker for Alzheimer\u2019s disease: a study with Brazilian elderly","volume":"35","author":"Manzine","year":"2013","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.nrleng.2026.502083_bib0175","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00406-018-0905-3","article-title":"Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer\u2019s disease patients","volume":"269","author":"Bram","year":"2019","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.nrleng.2026.502083_bib0180","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3233\/JAD-150737","article-title":"Increase of \u03b1-secretase ADAM10 in platelets along cognitively healthy aging","volume":"50","author":"Schuck","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.nrleng.2026.502083_bib0185","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/ph11010012","article-title":"Alpha-secretase ADAM10 regulation: insights into Alzheimer\u2019s disease treatment","volume":"11","author":"Peron","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.nrleng.2026.502083_bib0190","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1212\/WNL.0000000000001017","article-title":"Increased CSF APPs-\u03b1 levels in patients with Alzheimer disease treated with acitretin","volume":"83","author":"Endres","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2026.502083_bib0195","doi-asserted-by":"crossref","first-page":"e1298","DOI":"10.1212\/WNL.0000000000005290","article-title":"Midlife cardiovascular fitness and dementia: a 44-year longitudinal population study in women","volume":"90","author":"H\u00f6rder","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2026.502083_bib0200","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.nrleng.2026.502083_bib0205","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1523\/JNEUROSCI.0496-05.2005","article-title":"Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer\u2019s disease","volume":"25","author":"Adlard","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.nrleng.2026.502083_bib0210","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/jnc.14034","article-title":"Exercise and BDNF reduce A\u03b2 production by enhancing \u03b1-secretase processing of APP","volume":"142","author":"Nigam","year":"2017","journal-title":"J Neurochem"},{"key":"10.1016\/j.nrleng.2026.502083_bib0215","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1136\/jnnp-2012-304792","article-title":"Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial","volume":"84","author":"Mart\u00ednez-Lapiscina","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nrleng.2026.502083_bib0220","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/alz.12421","article-title":"Mediterranean and Western diet effects on Alzheimer\u2019s disease biomarkers, cerebral perfusion, and cognition in mid-life: a randomized trial","volume":"18","author":"Hoscheidt","year":"2022","journal-title":"Alzheimers Dement"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826000726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826000726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:34:39Z","timestamp":1792064079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580826000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2173580826000726"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.502083","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ADAM10 and its role in Alzheimer disease","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.502083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2026.502083","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502083"}}